Sanofi plans to offload its European generics business Zentiva that it acquired in 2009. Several bidders had earlier dropped out of an auction, but latest news suggests that the company is nearing an agreement and may soon finalize the sale.
According to Reuters, private equity firm Advent International has shown interest in acquiring the generic drug arm from the French healthcare company for about $2.48 billion (1.9 billion euros) including equity and debt. https://news.alphastreet.com/sanofi-nears-deal-to-sell-its-generic-business-unit-zentiva/
According to Reuters, private equity firm Advent International has shown interest in acquiring the generic drug arm from the French healthcare company for about $2.48 billion (1.9 billion euros) including equity and debt. https://news.alphastreet.com/sanofi-nears-deal-to-sell-its-generic-business-unit-zentiva/